Validation Study of the Korean Version of the EORTC QLQ-HDC29

N/ACompletedNCT01208532

Seoul National University Hospital226 enrolled

Overview

The aim of this study is to evaluate the reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer High-dose Chemotherapy module (EORTC HDC-29).

Study Type

OBSERVATIONAL

Enrollment

226

Conditions

Quality of Life After Stem Cell Transplantation

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who are aged more than 18 years * Patients who are diagnosed with hematologic malignancies and who are planned to receive high-dose chemotherapy followed by allogeneic or autologous stem cell transplantation (SCT) * Patients who agree with the informed consent Exclusion Criteria: * Patients who are unable to complete the questionnaire due to the serious physical or psychological morbidity

Locations (1)

Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Reliability and validity of the Korean version of the EORTC HDC-29

Relaibility; Cronbach's alpha coefficient is used to evaluate the internal consistency. Validity; Persons's correlation coefficient is used to examine the correlation between similar dimensions of the different questionnaires.

Time frame: at the patient's hospitalization (before the SCT) and the outpatient clinic (three, six, and 12 months after their SCT)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.